Jazz Pharmaceuticals plc Amortization of Intangible Assets
Jazz Pharmaceuticals plc (JAZZ) reported Amortization of Intangible Assets of $170.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-03
- Jazz Pharmaceuticals plc amortization of intangible assets for the quarter ending 2026-06-30 was $170.00M, a 4.87% increase year-over-year.
- Jazz Pharmaceuticals plc amortization of intangible assets for the quarter ending 2026-03-31 was $172.30M, a 11.59% increase year-over-year.
- Jazz Pharmaceuticals plc amortization of intangible assets for the quarter ending 2025-12-31 was $169.74M, a 6.82% increase year-over-year.
- Jazz Pharmaceuticals plc amortization of intangible assets for the quarter ending 2025-09-30 was $168.37M, a 6.93% increase year-over-year.
- Jazz Pharmaceuticals plc amortization of intangible assets for fiscal 2025 was $654.66M, a 4.36% increase from fiscal 2024.
- Jazz Pharmaceuticals plc amortization of intangible assets for fiscal 2024 was $627.31M, a 3.13% increase from fiscal 2023.
- Jazz Pharmaceuticals plc amortization of intangible assets for fiscal 2023 was $608.28M, a 1.52% increase from fiscal 2022.
- Jazz Pharmaceuticals plc amortization of intangible assets for fiscal 2022 was $599.17M, a 13.96% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $170.00M 10-Q · filed 2026-08-03 | $342.30M 10-Q · filed 2026-08-03 | $512.04M derived: sum of 3 quarters · filed 2026-08-03 | $680.41M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $172.30M 10-Q · filed 2026-05-05 | $342.04M derived: sum of 2 quarters · filed 2026-05-05 | $510.41M derived: sum of 3 quarters · filed 2026-05-05 | $672.51M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $169.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $338.11M derived: sum of 2 quarters · filed 2026-02-24 | $500.21M derived: sum of 3 quarters · filed 2026-08-03 | $654.66M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $168.37M 10-Q · filed 2025-11-05 | $330.47M derived: sum of 2 quarters · filed 2026-08-03 | $484.92M 10-Q · filed 2025-11-05 | $643.77M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $162.10M 10-Q · filed 2026-08-03 | $162.10M 10-Q · filed 2025-08-06 | $316.50M 10-Q · filed 2026-08-03 | $316.55M 10-Q · filed 2025-08-06 | $475.40M derived: sum of 3 quarters · filed 2026-08-03 | $632.86M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $154.40M 10-Q · filed 2026-05-05 | $154.45M 10-Q · filed 2025-05-07 | $313.30M derived: sum of 2 quarters · filed 2026-05-05 | $470.76M derived: sum of 3 quarters · filed 2026-05-05 | $625.98M derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $158.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $316.36M derived: sum of 2 quarters · filed 2026-02-24 | $471.58M derived: sum of 3 quarters · filed 2026-02-24 | $627.31M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $157.46M 10-Q · filed 2025-11-05 | $312.68M derived: sum of 2 quarters · filed 2025-11-05 | $468.41M 10-Q · filed 2025-11-05 | $619.96M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $155.22M 10-Q · filed 2025-08-06 | $310.95M 10-Q · filed 2025-08-06 | $462.51M derived: sum of 3 quarters · filed 2026-02-24 | $617.39M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $155.73M 10-Q · filed 2025-05-07 | $307.28M derived: sum of 2 quarters · filed 2026-02-24 | $462.17M derived: sum of 3 quarters · filed 2026-02-24 | $614.23M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $151.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $306.44M derived: sum of 2 quarters · filed 2026-02-24 | $458.50M derived: sum of 3 quarters · filed 2026-02-24 | $608.28M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $154.88M 10-Q · filed 2024-11-07 | $306.94M derived: sum of 2 quarters · filed 2024-11-07 | $456.73M 10-Q · filed 2024-11-07 | $594.12M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $152.06M 10-Q · filed 2024-08-01 | $301.85M 10-Q · filed 2024-08-01 | $439.24M derived: sum of 3 quarters · filed 2025-02-26 | $580.47M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $149.79M 10-Q · filed 2024-05-02 | $287.17M derived: sum of 2 quarters · filed 2025-02-26 | $428.40M derived: sum of 3 quarters · filed 2025-02-26 | $576.86M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $137.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $278.62M derived: sum of 2 quarters · filed 2025-02-26 | $427.07M derived: sum of 3 quarters · filed 2025-02-26 | $599.17M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $141.23M 10-Q · filed 2023-11-08 | $289.69M derived: sum of 2 quarters · filed 2023-11-08 | $461.78M 10-Q · filed 2023-11-08 | $619.08M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $148.46M 10-Q · filed 2023-08-09 | $320.55M 10-Q · filed 2023-08-09 | $477.84M derived: sum of 3 quarters · filed 2024-02-28 | $637.65M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $172.09M 10-Q · filed 2023-05-10 | $329.39M derived: sum of 2 quarters · filed 2024-02-28 | $489.19M derived: sum of 3 quarters · filed 2024-02-28 | $629.67M derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $157.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $317.10M derived: sum of 2 quarters · filed 2024-02-28 | $457.58M derived: sum of 3 quarters · filed 2024-02-28 | $525.77M 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $159.80M 10-Q · filed 2022-11-09 | $300.28M derived: sum of 2 quarters · filed 2022-11-09 | $368.48M 10-Q · filed 2022-11-09 | $435.55M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $140.48M 10-Q · filed 2022-08-03 | $208.67M 10-Q · filed 2022-08-03 | $275.75M derived: sum of 3 quarters · filed 2023-03-01 | $342.43M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $68.19M 10-Q · filed 2022-05-04 | $135.27M derived: sum of 2 quarters · filed 2023-03-01 | $201.95M derived: sum of 3 quarters · filed 2023-03-01 | $264.93M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $67.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $133.76M derived: sum of 2 quarters · filed 2023-03-01 | $196.73M derived: sum of 3 quarters · filed 2023-03-01 | $259.58M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $66.68M 10-Q · filed 2021-11-09 | $129.66M derived: sum of 2 quarters · filed 2021-11-09 | $192.50M 10-Q · filed 2021-11-09 | $366.00M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $62.97M 10-Q · filed 2021-08-03 | $125.82M 10-Q · filed 2021-08-03 | $299.31M derived: sum of 3 quarters · filed 2022-03-01 | $362.17M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $62.85M 10-Q · filed 2021-05-04 | $236.34M derived: sum of 2 quarters · filed 2022-03-01 | $299.20M derived: sum of 3 quarters · filed 2022-03-01 | $360.78M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $173.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $236.35M derived: sum of 2 quarters · filed 2022-03-01 | $297.93M derived: sum of 3 quarters · filed 2022-03-01 | $354.81M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $62.86M 10-Q · filed 2020-11-02 | $124.44M derived: sum of 2 quarters · filed 2020-11-02 | $181.32M 10-Q · filed 2020-11-02 | $227.87M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-06-30 | $61.58M 10-Q · filed 2020-08-04 | $118.46M 10-Q · filed 2020-08-04 | $165.00M derived: sum of 3 quarters · filed 2021-02-23 | $211.99M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-03-31 | $56.88M 10-Q · filed 2020-05-05 | $103.43M derived: sum of 2 quarters · filed 2021-02-23 | $150.42M derived: sum of 3 quarters · filed 2021-02-23 | $205.38M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2018-12-31 | $46.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $93.53M derived: sum of 2 quarters · filed 2021-02-23 | $148.49M derived: sum of 3 quarters · filed 2021-02-23 | $201.50M 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $46.99M 10-Q · filed 2019-11-05 | $101.95M derived: sum of 2 quarters · filed 2019-11-05 | $154.96M 10-Q · filed 2019-11-05 | $207.86M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $54.96M 10-Q · filed 2019-08-06 | $107.97M 10-Q · filed 2019-08-06 | $160.87M derived: sum of 3 quarters · filed 2020-02-25 | $208.18M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $53.01M 10-Q · filed 2019-05-07 | $105.91M derived: sum of 2 quarters · filed 2020-02-25 | $153.22M derived: sum of 3 quarters · filed 2020-02-25 | $179.41M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $52.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $100.21M derived: sum of 2 quarters · filed 2020-02-25 | $126.40M derived: sum of 3 quarters · filed 2020-02-25 | $152.06M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $47.31M 10-Q · filed 2018-11-06 | $73.50M derived: sum of 2 quarters · filed 2018-11-06 | $99.16M 10-Q · filed 2018-11-06 | $125.33M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $26.19M 10-Q · filed 2018-08-07 | $51.85M 10-Q · filed 2018-08-07 | $78.01M derived: sum of 3 quarters · filed 2019-02-26 | $104.47M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $25.66M 10-Q · filed 2018-05-08 | $51.83M derived: sum of 2 quarters · filed 2019-02-26 | $78.28M derived: sum of 3 quarters · filed 2019-02-26 | $105.02M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $26.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $52.62M derived: sum of 2 quarters · filed 2019-02-26 | $79.35M derived: sum of 3 quarters · filed 2019-02-26 | $101.99M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $26.45M 10-Q · filed 2017-11-07 | $53.19M derived: sum of 2 quarters · filed 2017-11-07 | $75.83M 10-Q · filed 2017-11-07 | $99.52M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $26.74M 10-Q · filed 2017-08-08 | $49.38M 10-Q · filed 2017-08-08 | $73.07M derived: sum of 3 quarters · filed 2018-02-27 | $99.20M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $22.64M 10-Q · filed 2017-05-09 | $46.33M derived: sum of 2 quarters · filed 2018-02-27 | $72.46M derived: sum of 3 quarters · filed 2018-02-27 | $96.13M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $23.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $49.82M derived: sum of 2 quarters · filed 2018-02-27 | $73.48M derived: sum of 3 quarters · filed 2018-02-27 | $98.16M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $26.13M 10-Q · filed 2016-11-08 | $49.80M derived: sum of 2 quarters · filed 2016-11-08 | $74.47M 10-Q · filed 2016-11-08 | $106.45M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $23.67M 10-Q · filed 2016-08-09 | $48.34M 10-Q · filed 2016-08-09 | $80.32M derived: sum of 3 quarters · filed 2017-02-28 | $110.95M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $24.68M 10-Q · filed 2016-05-10 | $56.65M derived: sum of 2 quarters · filed 2017-02-28 | $87.28M derived: sum of 3 quarters · filed 2017-02-28 | $120.08M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $31.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $62.61M derived: sum of 2 quarters · filed 2017-02-28 | $95.40M derived: sum of 3 quarters · filed 2017-02-28 | $126.58M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $30.63M 10-Q · filed 2015-11-09 | $63.42M derived: sum of 2 quarters · filed 2015-11-09 | $94.61M 10-Q · filed 2015-11-09 | $115.13M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-06-30 | $32.80M 10-Q · filed 2015-08-05 | $63.98M 10-Q · filed 2015-08-05 | $84.50M derived: sum of 3 quarters · filed 2016-02-23 | $104.06M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-03-31 | $31.18M 10-Q · filed 2015-05-07 | $51.71M derived: sum of 2 quarters · filed 2016-02-23 | $71.27M derived: sum of 3 quarters · filed 2016-02-23 | $90.67M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $20.52M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $40.09M derived: sum of 2 quarters · filed 2016-02-23 | $59.49M derived: sum of 3 quarters · filed 2016-02-23 | $79.04M 10-K · filed 2016-02-23 | ||
| 2013-09-30 | $19.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $38.96M derived: sum of 2 quarters · filed 2014-11-04 | $58.52M 10-Q · filed 2014-11-04 | $80.43M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-06-30 | $19.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $38.95M 10-Q · filed 2014-08-05 | $60.86M derived: sum of 3 quarters · filed 2015-02-24 | $82.61M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-03-31 | $19.55M 10-Q · filed 2014-05-08 | $41.46M derived: sum of 2 quarters · filed 2015-02-24 | $63.21M derived: sum of 3 quarters · filed 2015-02-24 | $78.96M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2012-12-31 | $21.91M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $43.66M derived: sum of 2 quarters · filed 2015-02-24 | $59.41M derived: sum of 3 quarters · filed 2015-02-24 | $72.92M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | $21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $37.50M derived: sum of 2 quarters · filed 2013-11-05 | $51.01M 10-Q · filed 2013-11-05 | $52.88M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | $15.75M 10-Q · filed 2012-08-07 | $29.26M 10-Q · filed 2013-08-06 | $31.13M derived: sum of 3 quarters · filed 2014-02-25 | $32.99M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-03-31 | $13.51M 10-Q · filed 2013-05-07 | $15.38M derived: sum of 2 quarters · filed 2014-02-25 | $17.24M derived: sum of 3 quarters · filed 2014-02-25 | $19.10M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2011-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $3.72M derived: sum of 2 quarters · filed 2014-02-25 | $5.59M derived: sum of 3 quarters · filed 2014-02-25 | $7.45M 10-K · filed 2014-02-25 | ||
| 2011-09-30 | $1.86M 10-Q · filed 2011-11-08 | $3.72M derived: sum of 2 quarters · filed 2012-08-07 | $5.59M 10-Q · filed 2012-11-09 | $7.45M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-06-30 | $1.86M 10-Q · filed 2012-08-07 | $3.72M 10-Q · filed 2012-08-07 | $5.59M derived: sum of 3 quarters · filed 2013-02-26 | $7.45M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-03-31 | $1.86M 10-Q · filed 2012-05-08 | $3.72M derived: sum of 2 quarters · filed 2013-02-26 | $5.59M derived: sum of 3 quarters · filed 2013-02-26 | $7.63M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2010-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $3.72M derived: sum of 2 quarters · filed 2013-02-26 | $5.77M derived: sum of 3 quarters · filed 2013-02-26 | $7.83M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $1.86M 10-Q · filed 2011-11-08 | $3.91M derived: sum of 2 quarters · filed 2011-11-08 | $5.96M 10-Q · filed 2011-11-08 | |||
| 2010-06-30 | $2.04M 10-Q · filed 2011-08-03 | $4.10M 10-Q · filed 2011-08-03 | ||||
| 2009-12-31 | $7.67M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |